Safety and Efficacy Study of Fluzone® Vaccine Combined With Different Doses of JVRS-100 Adjuvant

Completed · Phase 1

Conditions studied: Influenza

In brief

This study is designed to assess safety, tolerability and immunogenicity of Fluzone® vaccine with four dose levels of JVRS-100 adjuvant compared to Fluzone® vaccine alone in healthy adults 18-49 years of age.

Key facts

Study ID

NCT00662272

Run by

Colby Pharmaceutical Company

People needed

128

Starts

2008-06-01

Expected to finish

2009-12-01

Last updated by the study team

2010-03-17

Who can join

Age: 18 and older, up to 49. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• able to understand the study and provide written informed consent
• be age 18 to 49 years
• be in good general health, without significant medical history, physical examination findings, or abnormal laboratory results
• be available for the study duration, including all planned follow-up visits
• female subjects of child bearing potential must not be pregnant and agree to be correctly using an efficacious hormonal method of contraception or intrauterine device for at least 1 month before the study and during the study

You may not qualify if…

• have allergy to eggs or other components of the vaccine
• have had an influenza vaccine within 3 years preceding the screening visit
• have a history of severe reaction of any kind to conventional influenza vaccines
• have or suspected immunodeficiency disorder, including leukemia, lymphoma, generalized malignancy, or treatment with immunosuppressive medications, including corticosteroids, alkylating agents, antimetabolites, or radiation therapy
• have a history of an autoimmune disorder, including systemic lupus, rheumatoid arthritis, scleroderma, other collagen vascular disease, multiple sclerosis, etc. Psoriasis limited to cutaneous manifestations is not an exclusion criterion.
• have prior history of anaphylaxis to foods, hymenoptera stings, vaccines or drugs
• have had transfusion of blood or treatment with any blood product, including intramuscular or intravenous serum globulin within 3 months of the Screening Visit or anticipated through the study period
• have received another vaccine within 30 days preceding the screening visit or anticipated through the study period
• have participation in another clinical trial within 60 days of the screening visit
• have a positive serum or urine pregnancy test prior to vaccination or plan on a pregnancy during study period
• have abnormalities on laboratory assessment
• be seropositive to HIV or HCV or positive for HBsAg
• be positive for anti-nuclear antibodies
• have a physical examination indicating any clinically significant medical condition
• have a body temperature >38.1°C (100.6°F) or acute illness within 3 days prior to vaccination
• intention to travel out of the area prior to the study visit on Day 28 of the study
• have a history of excessive alcohol consumption, drug abuse, significant psychiatric illness
• have the intention to increase normal exercise routine, participate in contact sports or strenuous weight lifting or to initiate vigorous exercise from Screening until after Day 28 of the study

Where it is running

• Miami Research Associates — Miami, Florida, United States
• Johnson County Clin-Trials — Lenexa, Kansas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.